

Efficiency of transcutaneous electrical nerve stimulation in the treatment of central and peripheral disorders of the nervous system

Submission date 27/11/2024	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 02/12/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 06/05/2026	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Transcutaneous electrical nerve stimulation (TENS) has long been used in the treatment of pain of any etiology. For a long time, studies were carried out in an attempt to find out the secret of the analgesic effect of this method. Experimental studies have proven that TENS has three levels of action: local, segmental, and suprasegmental. Local effect develops by improving microcirculation and releasing anti-inflammatory drugs, stimulating cell regeneration and suppressing peripheral sensitization. The segmental analgesic effect is due to an increase in afferentation along fast fibers, causing stimulation of the gelatinous substance, and inhibiting afferentation along nociceptive fibers. Due to its suprasegmental action, TENS has an analgesic and anti-anxiety effect due to the release of central endorphins. However, there is not enough clinical research studying the recovery effect of TENS. In addition, there is no specific data on algorithms for the use of TENS in the treatment of various pathologies of the peripheral and central nervous system.

Who can participate?

Patients over 25 years of age who had pain due to pathology of the central or peripheral nervous system for more than 3 months.

What does the study involve?

Patients will be examined in different nosological groups. Currently, studies are planned in the following groups:

- Tension headache
- Migraine
- Post-stroke headache
- Peripheral and central sensory and motor deficit
- Cognitive disorders
- Cervicalgia
- Thoracalgia
- Low back pain
- Distal polyneuropathy

- Mononeuropathy
- Neurogenic erectile dysfunction
- Tunnel syndromes
- Meralgia paresthetica

Each group will be divided into 3 subgroups depending on the characteristics of the applied current: High-frequency low-amplitude TENS subgroup, Low-frequency high-amplitude TENS subgroup and Low-frequency low-amplitude TENS subgroup (Sham TENS).

What are the possible benefits and risks of participating?

The possible benefits of participating include relief from pain, improved motor and sensory function, and an overall improvement in quality of life. There are no known risks associated with participating in this study.

Where is the study run from?

Peoples' Friendship University of Russia (RUDN University), Medical Stomatology Institute

When is the study starting and how long is it expected to run for?

January 2023 to July 2029

Who is funding the study?

RUDN University

Who is the main contact?

Prof Al-Zamil Mustafa, mustafaalzamil33@gmail.com

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Prof Mustafa Al-Zamil

ORCID ID

<https://orcid.org/0000-0002-3643-982X>

Contact details

Peoples' Friendship University of Russia, Sherbinka, st. Rabochaya 2 - 42

Moscow-Sherbinka

Russian Federation

108851

+7 89262893810

alzamil@mail.ru

Additional identifiers

Protocol serial number

45453

Study information

Scientific Title

Analgesic and recovery effect of transcutaneous electrical nerve stimulation in treatment of central and peripheral neurological disorders

Acronym

TENS effect

Study objectives

To study the dynamics of pain, paresthesia, hypoesthesia and motor deficit after the use of transcutaneous electrical nerve stimulation in patients with pathology of the peripheral or central nervous system.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 05/04/2022, Local Medical Ethical Committee of Medical Dental Institute (Pskovskaya st. 7 - 1, Moscow, 127253, Russian Federation; +7 (499) 504-54-75; medinstmcbu@inbox.ru), ref: 3111

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Prevention, Safety, Treatment, Other

Health condition(s) or problem(s) studied

Pathology of the peripheral or central nervous system

Interventions

The treatment group receives effective transcutaneous electrical nerve stimulation. Each procedure lasts 20-30 minutes. The procedures are carried out 15 times every other day. In the control group, sham transcutaneous electrical nerve stimulation is carried out with electrical impulses of frequency 1 Hz, a duration - 50 μ s, and an amplitude - mA.

The randomization process will be conducted by program software: Statistica Version: 12.0.1133.15 (x86/x64)

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Transcutaneous electrical nerve stimulation

Primary outcome(s)

Current primary outcomes as of 06/05/2026:

Before treatment, a week after treatment, after 2 months and after 4 months of observation:

1. Pain assessment by visual analogue scale and McGill Pain Questionnaire
2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale
3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ)
4. Step activity monitoring by a pedometer
5. Motor deficit by 5-point scale
6. Electroneuromyography (ENMG):
 - 6.1. Amplitude of Compound Muscle Action Potential (CMAP):
 - 6.2. Terminal Latency
 - 6.3. Conduction Velocity
 - 6.4. Amplitude of Evoked Potential of Sural Nerves
 - 6.5. F-wave and A-wave Abnormalities
7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period.
8. Postural control examination and posturography

Previous primary outcomes:

Before treatment, a week after treatment, after 2 months and after 4 months of observation:

1. Pain assessment by visual analogue scale and McGill Pain Questionnaire
2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale
3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ)
4. Step activity monitoring by a pedometer
5. Motor deficit by 5-point scale
6. Electroneuromyography (ENMG):
 - 6.1. Amplitude of Compound Muscle Action Potential (CMAP):
 - 6.2. Terminal Latency
 - 6.3. Conduction Velocity
 - 6.4. Amplitude of Evoked Potential of Sural Nerves
 - 6.5. F-wave and A-wave Abnormalities
7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period.

Key secondary outcome(s)

Before treatment, a week after treatment, after 2 months and 4 months of observation:

1. Quality of life by SF-36 questionnaire
2. Quality of enjoyment by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF)
3. Assessment of sexuality disorders by the Sexual Function Evaluation Questionnaire (SFEQ)

Completion date

01/07/2029

Eligibility

Key inclusion criteria

1. European
2. Adults aged from 25 to 60 years old
3. Neurological disorder is older than 3 months but less than 2 years

4. The severity of pain by visual analogue scale (VAS) is 5 scores and higher
5. Changes in the neurophysiological examination of the nervous system: electromyography, electroencephalography, evoked potentials
6. Signed voluntary informed consent to participate in this study

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

25 years

Upper age limit

60 years

Sex

All

Total final enrolment

115

Key exclusion criteria

1. Presence of allergic reactions to any of the drugs used
2. Severe cognitive disorders
3. Epilepsy
4. Rheumatoid diseases
5. Atherosclerotic peripheral arterial disease of the lower extremities
6. Muscular dystrophies of the lower extremities
7. Diabetes mellitus
8. Pregnancy
9. Undergoing physiotherapy or acupuncture treatment

Date of first enrolment

04/01/2023

Date of final enrolment

01/07/2029

Locations**Countries of recruitment**

Russian Federation

Study participating centre

Medical Dental Institute

Pskovskaua 7-2
Moscow
Russian Federation
127253

Study participating centre

RUDN university
Miklucho-maklaya 6
Moscow
Russian Federation
117198

Sponsor information

Organisation

Peoples' Friendship University of Russia

ROR

<https://ror.org/02dn9h927>

Funder(s)

Funder type

University/education

Funder Name

RUDN University

Alternative Name(s)

Российский университет дружбы народов, Rossiysky universitet druzhby narodov, Université RUDN, Universidad de Rusia de la Amistad de los Pueblos, , Peoples' Friendship University of Russia

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

Russian Federation

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a publically available repository, RUDN Respiratory: <https://repository.rudn.ru/ru/records/dissertations/>. The type of data stored: Title of dissertations and scientific research.

IPD sharing plan summary

Stored in publicly available repository